Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 126, Issue 3, Pages 618-U360Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2010.06.007
Keywords
Asthma; inhaled corticosteroids; dual-specificity phosphatase 1; DUSP1; corticosteroid responsiveness
Categories
Funding
- American Asthma Foundation Strategic Program for Asthma Research
- National Institutes of Health [AI079139, AI061774, HL079055, DK064695, HL078885, AI077439, HL088133, U01 GM61390, ES015794]
- Fund for Henry Ford Hospital
- Flight Attendant Medical Research Institute (FAMRI)
Ask authors/readers for more resources
Background: Inhaled corticosteroids (ICSs) are considered firstline treatment for persistent asthma, yet there is significant variability in treatment response. Dual-specificity phosphatase 1 (DUSP1) appears to mediate the anti-inflammatory action of corticosteroids. Objective: We sought to determine whether variants in the DUSP1 gene are associated with clinical response to ICS treatment. Methods: Study participants with asthma were drawn from the following multiethnic cohorts: the Genetics of Asthma in Latino Americans (GALA) study; the Study of African Americans, Asthma, Genes & Environments (SAGE); and the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). We screened GALA study participants for genetic variants that modified the relationship between ICS use and bronchodilator response. We then replicated our findings in SAGE and SAPPHIRE participants. In a group of SAPPHIRE participants treated with ICSs for 6 weeks, we examined whether a DUSP1 polymorphism was associated with changes in FEV1 and self-reported asthma control. Results: The DUSP1 polymorphisms rs881152 and rs34507926 localized to different haplotype blocks and appeared to significantly modify the relationship between ICS use and bronchodilator response among GALA study participants. This interaction was also seen for rs881152 among SAPPHIRE but not SAGE participants. Among the group of SAPPHIRE participants prospectively treated with ICSs for 6 weeks, rs881152 genotype was significantly associated with changes in self-reported asthma control but not FEV1. Conclusion: DUSP1 polymorphisms were associated with clinical response to ICS therapy and therefore might be useful in the future to identify asthmatic patients more likely to respond to this controller treatment. (J Allergy Clin Immunol 2010;126:618-25.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available